Fortress Biotech, Inc.
FBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001429260
No open-market purchases or sales by Fortress Biotech, Inc. insiders were filed in the last 90 days; 55 institutions reported holding it in 13F filings for Q2 2026, worth $17.7M in total; no superinvestor holds it.
Other share classesFBIOP
Q3 2023 vs. Q2 2023
How the institutions holding Fortress Biotech, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 48 | 48 | 0 |
| Shares | 24.1M | 22.5M | −1.62M (−6.7%) |
| Value | $13.3M | $6.49M | −$6.79M (−51.1%) |
New holders (8)
Institutions that held Fortress Biotech, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wealth Enhancement Advisory Services, LLC | 1,542,000 | $447.6K | 0.00% |
| Bulltick Wealth Management, LLC | 70,000 | $20.3K | 0.01% |
| Jane Street Group, LLC | 59,822 | $17.4K | 0.00% |
| LPL Financial LLC | 37,000 | $10.7K | 0.00% |
| Platform Technology Partners | 30,000 | $8.71K | 0.00% |
| HRT Financial LP | 12,059 | $3.00K | 0.00% |
| Newbridge Financial Services Group, Inc. | 2,000 | $581 | 0.00% |
| Qube Research & Technologies Ltd | 40 | $12 | 0.00% |
Sold out (8)
Institutions that held Fortress Biotech, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Monticello Wealth Management, LLC | 408,000 | $224.4K |
| Raymond James & Associates | 44,480 | $24.5K |
| HighTower Advisors, LLC | 43,700 | $24.0K |
| Charles Schwab Investment Management Inc | 29,965 | $16.5K |
| Citadel Advisors LLC | 16,941 | $9.32K |
| Susquehanna International Group, LLP | 13,574 | $7.47K |
| Victory Capital Management Inc | 10,149 | $5.58K |
| Barclays PLC | 247 | $136 |